Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244543 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
A Phase 3 study of Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT00244543: Completed Phase 3 study of Allergic Conjunctivitis, sponsored by Vistakon Pharmaceuticals.
NCT00244543 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Vistakon Pharmaceuticals. The registered enrollment target is 110 participants, below the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244543, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Vistakon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
Conditions Studied
Interventions
- DRUG R89674 (generic name not yet established)
Study Locations (1)
Massachusetts
- - North Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00244543 record still lists
NCT00244543 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which R89674 (generic name not yet established) is the first listed.
NCT00244543 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00244543 about?
NCT00244543 is a clinical study titled "Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis". The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
What is the current status of trial NCT00244543?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2005-10.
What conditions does trial NCT00244543 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT00244543?
The interventions under investigation include: R89674 (generic name not yet established) (DRUG).
Who is sponsoring clinical trial NCT00244543?
This trial is sponsored by Vistakon Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00244543 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00244543's enrollment target sits among peer trials
110 9th of 20 higher than 12 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia